FREE MEMBERSHIP Includes » ABL Advisor eNews + iData Blasts | JOIN NOW ABLAdvisor Gray ABLAdvisor Blue
 
Skip Navigation LinksHome / Press Releases / Read Press Release

Print

Oxford Finance Provides $10MM Debt Financing to Celula

May 05, 2015, 07:24 AM
Filed Under: Medical


Oxford Finance LLC, a specialty finance firm that provides senior debt to life sciences and healthcare services companies, announced the closing of a $10 million senior secured term loan agreement with Celula, Inc., a diagnostic testing company focused on improving the accuracy of diagnosing major diseases, enabling better patient care and improved outcomes.  Proceeds of the loan will be used to continue the development and expand the commercialization of its products in the U.S. and China.

"Celula has a seasoned management team that has developed a novel platform technology for diagnostic testing services," said Christopher A. Herr, senior managing director for Oxford Finance. "We are glad to provide debt financing to Celula to support the growth of the company and the expansion of its product line."

"We are pleased to be working with Oxford Finance as a capital partner," said Dr. Drew Senyei, chairman and chief executive officer of Celula. "Oxford understood our needs and provided a well structured debt facility that fit Celula's business plan. We are looking forward to further developing and bringing our technology and unique approach to the diagnostic market to improve patient care."

Oxford Finance is a specialty finance firm providing senior secured loans to public and private life sciences and healthcare services companies worldwide. For over 20 years, Oxford has delivered flexible financing solutions to its clients, enabling these companies to maximize their equity by leveraging their assets. In recent years, Oxford has originated over $2 billion in loans, with lines of credit ranging from $500 thousand to $75 million.

Celula is a diagnostic testing services company focused on significantly improving the accuracy of diagnosing major diseases, enabling better patient care and improved outcomes.





Week's News



Comments From Our Members

You must be an ABL Advisor member to post comments. Login or Join Now.